1. 2003
2. Published

   Use of PK-PD modelling to predict the impact of non-compliance

   Hughes, D. & Hughes, D. A., 1 Nov 2003.

   Research output: Contribution to conference › Paper

3. Published

   Abacavir hypersensitivity: Is pre-prescription genotyping cost-effective?

   Hughes, D., Hughes, D. A. & Pirmohamed, M., 1 Sept 2003.

   Research output: Contribution to conference › Paper

4. Published

   Modelling changes in first line antimalarial therapy

   Hughes, D. & Hughes, D. A., 1 Sept 2003.

   Research output: Contribution to conference › Paper

5. Published

   Predicting "real world" effectiveness by integrating adherence with pharmacodynamic modelling.

   Hughes, D., Hughes, D. A. & Walley, T., 1 Jul 2003, In: Clinical Pharmacology and Therapeutics. 74, 1, p. 1-8

   Research output: Contribution to journal › Article › peer-review

6. Published

   Abacavir hypersensitivity: Is pre-prescription genotyping cost-effective?

   Hughes, D. & Hughes, D. A., 1 Jun 2003.

   Research output: Contribution to conference › Paper

7. Published

   Abacavir hypersensitivity: Is pre-prescription genotyping cost-effective?

   Hughes, D. & Hughes, D. A., 1 May 2003.

   Research output: Contribution to conference › Paper

8. 2002
9. Published

   Accurate and practical dosing of African populations using a height, weight and age model designed for lapdap

   Hughes, D., Hughes, D. A. & Bagust, A., 1 Nov 2002.

   Research output: Contribution to conference › Paper

10. Published

    Economic evaluation during early (phase II) trials

    Hughes, D. & Hughes, D. A., 1 Nov 2002.

    Research output: Contribution to conference › Paper

11. Published

    Impact of non-compliance on the cost-effectiveness of pharmaceuticals

    Hughes, D. & Hughes, D. A., 1 Nov 2002.

    Research output: Contribution to conference › Paper

12. Published

    Patient compliance and pharmacoeconomics

    Hughes, D. & Hughes, D. A., 1 Nov 2002.

    Research output: Contribution to conference › Paper